Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - nystatin, quantity: 500000 iu - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; ethanol; iron oxide yellow; titanium dioxide; gelatin; isopropyl alcohol; shellac; carbon black - indications as at 24 may 2005 : nilstat oral is indicated for the treatment of intestinal candidiasis.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - nystatin, quantity: 500000 iu - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; sodium starch glycollate; ethylcellulose; purified water; carnauba wax; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - indications as at 24 may 2005 : intestinal candidiasis.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - cyproterone acetate,ethinylestradiol -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - phenoxymethylpenicillin benzathine -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; gelatin; calcium hydrogen phosphate dihydrate; maize starch; ethylcellulose; sorbitol; titanium dioxide; macrogol 6000 - indications as at 04 jan 2002 : oral administation : myambutol is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculois meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculous of the shin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjuction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs - myambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months for example, myambutol plus isoniazid plus rifampicin or myambutol plus isoniazid plus streptomycin then continuing with a two drug regimen such as myambutol plus isoniazid or myambutol plus rifampicin. in patients who have received previous antituberculosis therapy, mycobacterial resistance to other durgs used in initial therapy is frequent. consequently, in such retreatment cases myambutol should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculosis drugs used with myambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been use in multiple drug regimens. alternating drug regimens have also been utilised.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - cyproterone acetate,ethinylestradiol -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - bicalutamide, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; povidone; sodium starch glycollate; titanium dioxide; hypromellose; macrogol 400 - treatment of advanced prostate cancer in combination with lhrh agonist therapy. prevention of disease flare associated with the use of lhrh agonists.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - perhexiline maleate, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch; purified talc; sucrose; lactose monohydrate - to reduce the frequency of moderate to severe attacks of angina pectoris due to coronary artery disease in patients who have not responded to other conventional therapy or in whom such therapy may be contra-indicated. note: because of the serious nature of potential side effects, perhexiline maleate should be reserved for use in patients with intractable angina who are refactory or intolerant to other agents and who are not suitable canditates for coronary bypass surgery.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - ethambutol hydrochloride, quantity: 100 mg - tablet, film coated - excipient ingredients: sorbitol solution (70 per cent) (non-crystallising); sucrose; gelatin; stearic acid; magnesium stearate; quinoline yellow; purified water; purified talc; shellac; industrial methylated spirit; povidone; acetylated monoglycerides - indications as at 04 jan 2002 : oral administation : myambutol is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculois meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculous of the shin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjuction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs - myambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 mo

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - atropine sulfate monohydrate, quantity: 9.9737 mg/ml - eye drops, solution - excipient ingredients: boric acid; disodium edetate; benzalkonium chloride; hypromellose; water for injections - indications as at 06 august 1999: atropt eye drops are indicated where it is necessary to dilate the pupil and paralyse accomodation.